| Title: |
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis |
| Authors: |
Murthy, Hemant S; Zhang, Mei-Jie; Chen, Karen; Ahmed, Sairah; Deotare, Uday; Ganguly, Siddhartha; Kansagra, Ankit; Michelis, Fotios V; Nishihori, Taiga; Patnaik, Mrinal; Abid, Muhammad Bilal; Aljurf, Mahmoud; Arai, Yasuyuki; Bacher, Ulrike; Badar, Talha; Badawy, Sherif M; Ballen, Karen; Battiwalla, Minoo; Beitinjaneh, Amer; Bejanyan, Nelli; Bhatt, Vijaya Raj; Brown, Valerie I; Martino, Rodrigo; Cahn, Jean-Yves; Castillo, Paul; Cerny, Jan; Chhabra, Saurabh; Copelan, Edward; Daly, Andrew; Dholaria, Bhagirathbhai; Diaz Perez, Miguel Angel; Freytes, César O; Grunwald, Michael R; Hashmi, Shahrukh; Hildebrandt, Gerhard C; Jamy, Omer; Joseph, Jacinth; Kanakry, Christopher G; Khera, Nandita; Krem, Maxwell M; Kuwatsuka, Yachiyo; Lazarus, Hillard M; Lekakis, Lazaros J; Liu, Hongtao; Modi, Dipenkumar; Munshi, Pashna N; Mussetti, Alberto; Palmisiano, Neil; Patel, Sagar S; Rizzieri, David A; Seo, Sachiko; Shah, Mithun Vinod; Sharma, Akshay; Sohl, Melhm; Solomon, Scott R; Ulrickson, Matthew; Ustun, Celalettin; van der Poel, Marjolein; Verdonck, Leo F; Wagner, John L; Wang, Trent; Wirk, Baldeep; Zeidan, Amer; Litzow, Mark; Kebriaei, Partow; Hourigan, Christopher S; Weisdorf, Daniel J; Saber, Wael; Kharfan-Dabaja, Mohamed A |
| Contributors: |
Medicine |
| Source: |
Blood advances ; 7 ; 22 ; 7007 ; 7016 ; United States |
| Publication Year: |
2025 |
| Collection: |
University of Massachusetts, Medical School: eScholarship@UMMS |
| Description: |
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT) offers durable remissions in patients with BPDCN. We report an analysis of patients with BPDCN who received an allo-HCT, using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We identified 164 patients with BPDCN from 78 centers who underwent allo-HCT between 2007 and 2018. The 5-year overall survival (OS), disease-free survival (DFS), relapse, and nonrelapse mortality (NRM) rates were 51.2% (95% confidence interval [CI], 42.5-59.8), 44.4% (95% CI, 36.2-52.8), 32.2% (95% CI, 24.7-40.3), and 23.3% (95% CI, 16.9-30.4), respectively. Disease relapse was the most common cause of death. On multivariate analyses, age of ≥60 years was predictive for inferior OS (hazard ratio [HR], 2.16; 95% CI, 1.35-3.46; P = .001), and higher NRM (HR, 2.19; 95% CI, 1.13-4.22; P = .02). Remission status at time of allo-HCT (CR2/primary induction failure/relapse vs CR1) was predictive of inferior OS (HR, 1.87; 95% CI, 1.14-3.06; P = .01) and DFS (HR, 1.75; 95% CI, 1.11-2.76; P = .02). Use of myeloablative conditioning with total body irradiation (MAC-TBI) was predictive of improved DFS and reduced relapse risk. Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. Novel strategies incorporating allo-HCT are needed to further improve outcomes. ; No embargo |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
37792849 |
| Relation: |
Blood Advances; https://doi.org/10.1182/bloodadvances.2023011308; 498210; https://hdl.handle.net/20.500.14038/54719 |
| DOI: |
10.1182/bloodadvances.2023011308 |
| Availability: |
https://doi.org/10.1182/bloodadvances.2023011308; https://hdl.handle.net/20.500.14038/54719 |
| Rights: |
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ; http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.B4CF4138 |
| Database: |
BASE |